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     Breast cancer is a common malignancy 
comprising 24.4% of all cancers and is the leading 
cause of death among Iranian women (1, 2). 
Approximately 5–10% of all breast cancers are 
attributable to the strong hereditary susceptibility, 
highly penetrant genes, such as BRCA1/2 (3). 
Women carrying germ line mutations in these genes 
have an extremely high lifetime risk of developing 
breast and/or ovarian cancer (4). Among Carriers of 
BRCA1/2 mutations, the Lifetime risk of breast 
cancer is 56% to 84% by age 70 (4-7). Estimation 
the mutation probability is important for various 
Breast cancer is a prevalent malignancy among women 
worldwide and a principle reason of death in Iranian 
women. In current study, 64 Iranian women diagnosed 
with breast cancer and classified into four age groups (<35 
years, 35–49 years, 50–64 years and >65 years) were 
analyzed for correlation between heterozygote risk and 
lifetime risk with clinicopathological features. Nine 
patients were also investigated for BRCA1 germline 
mutations. Our results indicated that people with 
hetrozygosity risk over 30% more likely to infect invasive 
ductal carcinoma and utilization of Cyrillic software for 
Iranian family would open new sights towards the 
prediction, prognosis and mutation detection. 
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reasons including the cost of genetic testing, the low 
probability of mutations that concerned patients and 
the psychosocial reasons(8). Breast cancer risk 
determination plays an important role to select an 
appropriate strategy of disease management (9). 
To date, correlation of in vitro heterozygote risk and 
lifetime risk of breast cancer patients with 
clinicopathologic features have not been described in 
Iran population.  In this research we estimated the 
probability of carrying of mutations in BRCA1 by 
risk evaluation program and correlation between 
heterozygote risk and lifetime risk of breast cancer 
patients with age, weight, histological type, 
menopausal status, lymph node status, histological 
grade, tumor stage, Diabetes status and expression of 
five immunohistochemical markers (ER, PR, HER-
2, P53 and Ki67) investigated. 
  
Materials and methods 
Patients: A study was conducted with 64 Iranian 
women diagnosed with breast cancer who were 
referred to the Ghaem Hospital of Mashhad 
University of Medical Sciences between 2010 and 
2013. After genetic counseling of index cases with 
breast cancer and obtaining a written informed 
consent, demographic information, family-history 
and hormone receptor status of breast cancer patients 
were archived to a database. The individual's risk of 
heterozygosity and the lifetime risk for breast cancer 
were assessed by Cyrillic 3.1 (an established 
pedigree drawing program designed for clinical 
geneticist). 
Data Collection: The patients were classified into 
four age groups: <35 years, 35–49 years, 50–64 
years and >65 years. Age of 35 as cut-off point to 
define young age breast cancer was regarded. A 
clinical and pathology information such as patient 
age, weight, histological type, tumor stage, 
menopausal status, lymph node status, histological 
grade,  ER, PR, HER-2, P53 and Ki67 status were 
extracted from medical and pathology records.  
DNA Extraction and Polymerase Chain Reaction: 
Genomic DNA was extracted from peripheral whole 
blood samples (9 breast or ovarian cancer patients 
were selected for BRCA1 germline mutations 
analysis) using standard procedure (salting out). All 
of 24 exons of BRCA1 gene were amplified by PCR 
using 34 pairs of exon-specific primers. 
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 PCR was performed using GenetBio kit with the 
following program: 2 min at 94°C, 30 s at 94°C, 30 s 
at 54-64°C, and 1 min at 72°C  for 35 cycles in a 25 
μl reaction volume. 
BRCA1 Sequence Analysis 
For mutational analysis, PCR products were 
sequenced using forward or reverse primers by a 
commercial sequencing company (Macrogen, 
Korea) and the results was analyzed using 
SeqScape® Software Version 2.7. Finally, all 
detected variants were checked by BIC and HGMD 
database. 
Statistical analysis 
Statistical analysis was performed using the SPSS 
11.0 statistical package (SPSS, Chicago, IL). All 
data were expressed as mean ± s.d. and analyzed by t 
test or ANOVA. P-value ≤ 0.05 was considered 
statistically significant. 
Results 
Demographic and Clinicopathological 
Characteristics 
In the overall study group, the mean ages ± SD at 
diagnosis of studied patients was 44.3±10.0 years. 
64 patients were diagnosed with unilateral breast 
cancer that Invasive Ductal Carcinoma (IDC) was 
the most common form between studied patients and 
others were comedo carcinoma, infiltrating ductal 
carcinoma, medullary carcinoma, invasive papillary 
carcinoma and mucinous carcinoma. Histological 
grade of the patients were grade 1 (8 cases), grade 2 
(27 cases) and grade 3 (18 cases). Tumor stage 
classification were stage 1 (8 cases), stage II (32 
cases), stage III (9 cases) and stage IV (6 cases). 
Four patients had diabetes at diagnosis and the 
remaining patients (60 cases) were categorized as 
non-diabetic.  
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<35yr / n=7 35-49yr / n=36 50-64yr / =18 65+yr / n=3 
Weight(mean) 63.78 69.88 74.60 58.00 
  
Unilateral 
  
7(100%) 
  
36(100%) 
  
18(100%) 
  
2(66.7%) 
Histology 
Invasive ductal carcinoma 
Comedo carcinoma 
Infiltrating  ductal carcinoma 
Medullary carcinoma 
Invasive papillary carcinoma 
Mucinous carcinoma 
  
5(71.4%) 
1(14.3%) 
1(14.3%) 
0 
0 
0 
  
32(88.9%) 
0 
3(8.35%) 
0 
0 
1(2.8%) 
  
13(72.2%) 
2(11.1%) 
0 
1(5.6%) 
1(5.6%) 
1(5.6%) 
  
3(100%) 
0 
0 
0 
0 
0 
Grade 
I 
II 
III 
Unknown/not done 
  
0 
3(42.9%) 
3(42.9%) 
1(14.3%) 
  
3(8.3%) 
20(55.6%) 
9(25%) 
4(11.1%) 
  
4(22.2%) 
4(22.2%) 
4(22.2%) 
6(33.3%) 
  
1(33.3%) 
0 
2(66.7%) 
0 
TNM-stage 
 I 
II 
III 
IV 
Unknown/not done 
  
1(14.3%) 
2(28.6%) 
3(42.9%) 
1(14.3%) 
0 
  
2(5.6%) 
21(58.3%) 
4(11.1%) 
4(11.1%) 
5(13.9%) 
  
5(27.8%) 
8(44.4%) 
1(5.6%) 
1(5.6%) 
3(16.7%) 
  
0 
1(33.3%) 
1(33.3%) 
0 
1(33.3%) 
menopausal status 
Premenopausal 
Postmenopausal 
  
7(100%) 
0 
  
33(91.7%) 
3(8.3%) 
  
4(22.2%) 
14(77.8%) 
  
0 
3(100%) 
Diabetes status 
Positive 
Negative 
  
0 
7(100%) 
  
2(5.6%) 
34(94.4%) 
  
2(11.1%) 
16(88.9%) 
  
0 
3(100%) 
Table1: Demographic characteristics of 64 patients by age category 
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We classified the patients based on menopausal 
status at diagnosis, 44 pa­tients (68.8%) were 
premenopausal, while 20 patients (31.2%) 
postmenopausal (table 1).  
Risk Assessment  
Heterozygote and lifetime risk of breast cancer 
patients before the age of 85 years were assessed by 
Cyrillic 3.1. The heterozygote risk was estimated to 
be 39.81% (<35 yr), 34.21% (35–49 yr), 9.93% (35–
49 yr) and 6.00% (>65 yr). The majority of lifetime 
risk in 10, 20 and 30 years were assigned in age of 
<35 (table 2). Furthermore, the risk to age 85 years 
of patients was 43.11% (<35 yr), 33.43% (35–49 yr), 
14.74% (35–49 yr) and 13.53% (>65 yr), 
respectively (table2). 
Vol. 3, No. 2, jun, 2017 
Table2: Risk assessment of 64 patients by age category 
  
  
  
<35yr 
n=7 
N(%) 
35-49yr 
n=36 
N(%) 
50-64yr 
n=18 
N(%) 
65+yr 
n=3 
N(%) 
Heterozygote Risk 39.81 34.21 9.93 6.00 
10 years risk 7.51 7.90 3.41 2.70 
20 years risk 16.97 15.30 6.83 4.30 
30 years risk 25.07 21.26 11.71 7.90 
Risk to age 85 43.11 33.43 14.74 13.53 
Immunohistochemical Characteristics 
Expression of five immunohistochemical markers 
included ER, PR, HER-2, Ki67 and P53 status in 
tumors were positive in 73.4%, 64.1%, 14.1%, 
23.4% and 20.3% and negative in 23.4%, 33%, 
78.1%, 23.4% and 25% cases, respectively (table 3).  
  
  
  
<35yr 
n=7 
35-49yr 
n=36 
50-64yr 
n=18 
65+yr 
n=3  
*ER 
Positive 
Negative 
Unknown/not done 
  
5(71.4%) 
2(28.6%) 
0 
  
28(77.8%) 
8(22.2%) 
0 
  
12(66.7%) 
5(27.8%) 
1(5.6%) 
  
2(66.7%) 
0 
1(33.3%) 
†PR 
Positive 
Negative 
Unknown/not done 
  
3(42.9%) 
4(57.1%) 
0 
  
26(72.2%) 
10(27.8%) 
0 
  
11(61.1%) 
6(33.3%) 
1(5.6%) 
  
1(33.3%) 
1(33.3%) 
1(33.3%) 
HER-2 
Positive 
Negative 
Unknown/not done 
  
2(28.6%) 
5(71.4%) 
0 
  
1(2.8%) 
32(88.9%) 
3(8.3%) 
  
4(22.2%) 
13(72.2%) 
1(5.6%) 
  
2(66.6%) 
0 
1(33.3%) 
Ki67 
Positive 
Negative 
Unknown/not done 
  
3(42.9%) 
1(14.3%) 
3(42.9%) 
  
8(22.2%) 
9(25.0%) 
19(52.8%) 
  
3(16.7%) 
5(27.8%) 
10(55.6%) 
  
1(33.3%) 
0 
2(66.7%) 
P53 
Positive 
Negative 
Unknown/not done 
  
2(28.6%) 
2(28.6%) 
3(42.9%) 
  
7(19.4%) 
10(27.8%) 
19(52.8%) 
  
4(22.2%) 
3(16.7%) 
11(61.1%) 
  
0 
1(33.3%) 
2(66.7%) 
Table3: Immunohistochemical of 64 patients by age category 
* Estrogen receptor, † Progesterone receptor 
Ardalan and  Sadr-Nabavi   2017. The Cancer Press, 3(2): 67-73                                                                                                           70 
www.thecancerpress.com 
www.imaqpress.com  
Association between the heterozygote and lifetime 
risk of breast cancer patients with 
clinicopathological characteristics  
We compared heterozygote and lifetime risk 
between different groups of population and tumor 
characteristic features. Our results showed a 
significant difference between heterozygote risk and 
lifetime risk of different groups of age (P<0.01). The 
risk at age 85 was also statistically significant 
between the two groups of premenopausal and 
postmenopausal breast cancer patients (P<0.001) 
(table 4). However, there was no statistically 
significant difference across the age groups between 
the heterozygote risk and lifetime risk in breast 
cancer patients and Weight, histological type, 
histological grade, tumor stage and Diabetes status 
(P>0.05) (table 4). 
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Heterozygote risk 
P-value 
10 years risk 
P-value 
20 years risk 
P-value 
30 years risk 
P-value 
Risk to age 85 
  
P-value 
Age (<35,35-49,50-65,+65) 0.004*       0.000* 
weight r=-0.182, p=0.156 ۩ 
r=-0.150, 
p=0.244 ۩ 
r=-0.195, 
p=0.132 ۩ 
r=-0.227, 
p=0.095 ۩ 
r=-0.233, 
p=0.068 ۩ 
Side 0.552§ 0.338§ 0.381§ 0.384§ 0.742§ 
Histology 0.602*       0.619* 
Grade 0.403* 0.587* 0.605* 0.731* 0.252* 
Stage 0.426* 0.436* 0.531* 0.600* 0.533* 
ER status 0.367§ 0.625§ 0.453§ 0.404§ 0.327§ 
PR status 0.215§ 0.402§ 0.358§ 0.358§ 0.191§ 
HER-2  status 0.060§ 0.281§ 0.042§ 0.161§ 0.265§ 
Ki67 0.800§ 0.453§ 0.708§ 0.687§ 0.802§ 
P53 0.761§ 0.779§ 0.821§ 0.940§ 0.753§ 
pre/postmenopausal 0.250§ 0.045§ 0.027§ 0.315§ 0.000§ 
Diabetes status 0.201§ 0.140§ 0.216§ 0.145§ 0.538§ 
Table 4: Analyzing heterozygote risk and lifetime risk between different variables   
* One-Way ANOVA 
§ Independent-Sample T test 
۩correlation test 
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Table 5: list of all mutations and variants identified in all nine patients 
Patient ID Exon DNA Mutation* Amino Acid Change Type 
  
  
  
  
  
1 
2 IVS1-115T>C - 1PM 
7 7+18delCTT -7:c.-19-115T>C PM 
8 IVS7-34T>C - PM 
  
c.3548  A>G p. Lys1183Arg 2UV 
c.2430  T>C p. Leu1177Ile PM 
13 c.4427T>C p. Ser1305Ser UV 
18 IVS19+66G>A - IVS 
  
2 
8 IVS8-33T>C - PM 
10 IVS10-34T>G - PM 
11 c.1067   A>G p.Gln356Arg UV 
3 7 7+32delCT - PM 
  
  
4 
2 IVS1-115 T>C - IVS 
9 IVS9- 49 del T - IVS 
11 c.2077  G>A p. Asp693Asn UV 
  
5 
7 7+32del CT   PM 
  
11 c.3508  A>T p.Ile1170Asn UV 
  
  
  
  
6 
7 7+18del CTT - PM 
  
c.3113   A>G p.Glu1038Gly UV 
c.3548  A>G p.lys1183Arg UV 
16 
  
c.4837   A>G p. Ser1613Gly UV 
c.4956   G>A p.Met1652Ile UV 
  
  
7 
  
7 
  
7+32delCT - PM 
7+18delCTT - PM 
8 IVS8-35T>C - PM 
  
11 
  
c.1186  A>G p.Gln356Arg UV 
c.1009  T>A p.Met297Lys UV 
  
8 
7 7+32delPolyT - PM 
14 c.4463-4464 (insA) p.Asn1488 PM 
9 7 7+32delCT - PM 
BRCA1 Mutation Analysis 
According to inclusion criteria and genetic 
counseling, nine breast or ovarian cancer patients 
were analyzed for BRCA1 germline mutations 
analysis. In patients’ pedigree, the information about 
the proband and the relatives with breast and/or 
ovarian cancer has been demonstrated 
(Supplementary 1). Different mutations in BRCA1 
gene were identified in the patients (table 5). 
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Discussion 
Breast cancer (BC) is one of the common cancer 
between women in worldwide and the top 
malignancy in Iranian women over the past few 
decades (10). It has been reported that the mutation 
of BRCA1/2 have been found in 2–6% of breast 
cancer patients (7, 11, 12). BC at a younger age is 
also related to the disease advanced stage, higher 
grade, ER negativity and BRCA1 ectopic expression
(13). In this study we compared the heterozygote 
risk and lifetime risk between different groups of our 
population and tumor characteristic features. 45–
80% lifetime risk of breast cancer has been 
estimated in carriers of BRCA1 and BRCA2 
mutations (4, 7). In our results heterozygote risk and 
lifetime risk had a significant difference between 
diverse groups of age (P<0.01). The risk to age 85 
was statistically significant between the two groups 
of premenopausal and postmenopausal breast cancer 
patients (P<0.001). Meanwhile, there was no 
statistically significant difference across the age 
groups between the heterozygote risk and lifetime 
risk in breast cancer patients and clinicopathological 
traits (P>0.05). 
Association between 20 years risk of breast cancer 
patients and other clinicopathological characteristics 
was merely statistically significant for expression of 
HER-2 and other factor (ER, PR, Ki67 and P53) 
were not significant.  
Different studies in Iran demonstrated various 
alterations of BRCA1 and BRCA2 genes. In our 
previous study we had introduced a novel mutation 
in Khorasan papulation (accession number 
BankIt1473921 JN686490) (14). However, due to 
the sequencing of nine patients in present study, not 
only we found out submitted mutation, but also, no 
novel mutations did not determine in BRCA1 gene 
exons. 
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Conclusion 
Our data recommended which utilization of Cyrillic software for Iranian family would open new sights 
towards the prediction, prognosis and mutation detection. People with heterozygote risk over 30% are more 
likely to be infect invasive ductal carcinoma and are a good candidate for the BRCA1 and BRCA2 gene 
mutations. So far, for Iranian Breast Cancer affected Families, the Cyrillic is appropriate Software for the 
prediction of genetic diagnostic for BRCA1 and BRCA2. However, sample size and limitations of medical 
records of patients are two major limitations should be considered in future studies.  
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